Table 4.
Top canonical pathways regulated by genes specifically up- or downregulated in microglia and astrocytes in response to Th1-derived effectors.
| Ingenuity canonical pathways | –log(p-value) | Molecules |
|---|---|---|
| (A) ASTROCYTES | ||
| Axonal guidance signaling | 6.16 | NTF3,ADAMTS8,RND1,BMP4,SLIT1,MYL2,ITSN1,BDNF,BMP2,CXCL12,SEMA4C,EPHB6,FGFR3, NTNG1,SEMA6D,EPHB1,TUBA8,FGFR4,PLXNB3,GNG12,UNC5C,PAK4,TUBB3,PAK6,ARHGEF15, VEGFC,DPYSL5,ROBO3,PLXND1,PDGFB,WNT10A,EPHB3,EPHA5,BMP7,BMP6,GLI1 |
| Hepatic fibrosis/hepatic stellate cell activation | 4.43 | COL8A2,CTGF,MYL2,COL2A1,VEGFC,MYH7,IL6,MYH7B,PDGFB,COL26A1,FGF1,COL16A1, COL5A3,HGF,COL4A4,COL11A1,COL9A2,TNFRSF11B |
| FGF Signaling | 3.79 | FGFR3,FGF18,FGF9,HGF,FGFR4,FGF14,FGF12,FGF23,CREB5,MAPK11,FGF1 |
| Cellular effects of sildenafil (Viagra) | 3.49 | SLC4A5,Ppp1r12b,CACNA1S,MYL2,GPR37,CACNG4,ADCY1,GUCY1A2,CACNA1C, MYH7,KCNH2,MYH7B,Gucy1b2 |
| Cardiomyocyte differentiation via bmp receptors | 3.45 | BMP4,MYL2,BMP2,BMP7,MYH7 |
| Bladder cancer signaling | 3.28 | FGFR3,FGF18,FGF9,MMP15,FGF14,FGF12,FGF23,VEGFC,MMP17,FGF1 |
| Ephrin receptor signaling | 2.78 | PAK4,ITSN1,PAK6,ARHGEF15,CXCL12,VEGFC,CREB5,PDGFB,FGF1, EPHB6,EPHB1,EPHB3,EPHA5,GNG12 |
| Corticotropin releasing hormone signaling | 2.74 | NOS1,CACNA1S,CACNG4,BDNF,ADCY1,MEF2A,GUCY1A2,CACNA1C,CREB5, MAPK11,GLI1,Gucy1b2 |
| Actin cytoskeleton signaling | 2.53 | PAK4,MYL2,PAK6,FGF9,FGF14,MYH7,MYH7B,PDGFB,FGF1,FGFR3, Ppp1r12b,FGF18,FGFR4,FGF12,FGF23,GNG12 |
| BMP signaling pathway | 2.51 | SOSTDC1,BMP4,SMAD9, BMP2,BMP7,BMP6,MAPK11,SMURF1 |
| (B) MICROGLIA | ||
| G-Protein coupled receptor signaling | 8.55 | NAPEPLD,HTR2B,RGS18,ADCY4,ADORA3,HTR1D,CHRM3,MPPE1,BRAF,LTB4R,PDE7B,PDE3B, PIK3CG,RGS10,HTR7,RGS14,ADORA2B,RASA1,SRC,FPR2,PDE1C,ADCY9,P2RY13,PLCB4, DUSP9,PRKAR2B,LPAR1,PRKAG2,PIK3R6,S1PR1,P2RY12, PIK3CD,DUSP4,PTGER2,ADCY7,PRKCB |
| Colorectal cancer metastasis signaling | 6.54 | MMP7,TGFBR1,MMP14,ADCY4,FZD1,PDGFC,BRAF,GNG11,PIK3CG,TLR1,CTNNB1,WNT5B, RALGDS,Tlr11,SRC,CASP3,GRK3,TYK2,IFNGR1,ADCY9,PRKAR2B,TLR6,MSH6,PRKAG2, PIK3R6,Tlr13,PIK3CD,PTGER2,JAK3,ADCY7 |
| cAMP-mediated signaling | 6.28 | NAPEPLD,RGS18,ADCY4,ADORA3,HTR1D,CHRM3,MPPE1,BRAF,LTB4R,PDE7B,PDE3B, RGS10,HTR7,ADORA2B,RGS14,SRC,FPR2,PDE1C,ADCY9,P2RY13,DUSP9,PRKAR2B, LPAR1,S1PR1,P2RY12,DUSP4,PTGER2,ADCY7 |
| Phagosome formation | 6.14 | Tlr11,C5AR1,PRKCQ,FCGR2A,PLCL2,FCGR2B,FCGR1A,PLCD1,PLCB4,Fcrls, SCARA3,PIK3CG,TLR6,TLR1,PIK3R6,Tlr13,PRKCH,PIK3CD,C3AR1,PRKCB |
| Superpathway of cholesterol biosynthesis | 5.83 | FDPS,FDFT1,NSDHL,ACAT2,IDI1,MSMO1,TM7SF2,SC5D,CYP51A1 |
| Gαi signaling | 5.48 | SRC,ADCY4,FPR2,ADORA3,HTR1D,ADCY9,P2RY13,LTB4R,GNG11,PRKAR2B, LPAR1,RGS10,S1PR1,PRKAG2,P2RY12,RGS14,ADCY7,RALGDS |
| Molecular mechanisms of cancer | 4.8 | CDKN2A,RAP2A,TGFBR1,ADCY4,CDKN2C,HIF1A,FZD1,BRAF,CCND3,PIK3CG, CTNNB1,RASA1,RALGDS,WNT5B,CDK18,SRC,ARHGEF4,PRKCQ, CASP3,GNA12,TYK2,CDK6,ADCY9,ARHGEF5,PLCB4,MAX,PRKAR2B, CCND2,PRKAG2,PIK3R6,PIK3CD, PRKCH,CDK19,JAK3,ADCY7,PRKCB |
| Zymosterol biosynthesis | 4.34 | NSDHL,MSMO1,TM7SF2,CYP51A1 |
| Gustation pathway | 3.98 | GNAT3,NAPEPLD,ADCY4,CACNB4,P2RX5,CACNA1A,PDE1C,MPPE1, ADCY9,P2RY13,LPAR6,GNG11,PRKAR2B,PDE7B,PDE3B,PRKAG2,P2RY12,ADCY7 |
| eNOS signaling | 3.84 | PRKCQ,CASP3,ADCY4,CHRM3,PDGFC,HSPA1L,NOSTRIN,ADCY9, LPAR6,PRKAR2B,LPAR1,PIK3CG,PIK3R6,PRKAG2,PRKCH,PIK3CD,ESR1,ADCY7,PRKCB |